Dr. Nadar N. Youssef
Dr. Nader N. Youssef is a board certified gastroenterologist specializing in the treatment of adolescent patients between 13-21 years of age who are suffering from Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) such as Crohn’s, Celiac Disease, Eosinophilic Esophagitis, CHO intolerance, bacterial overgrowth, and restrictive eating behavior. He is an Associate Professor of Pediatrics at the New Jersey Medical School, Newark and Assistant Professor at the Rutgers School of Health Related Professions- Institute for Complementary and Alternative Medicine.
Prior to his current positions, Dr. Youssef established the Center for Pediatric Irritable Bowel and Motility Disorders in 2003 at the Goryeb Children’s Hospital Atlantic Health System in Morristown, NJ, and was its director until 2009. It is the only center in New Jersey, New York and Connecticut dedicated to gastrointestinal evaluation of children, including motility testing.
He completed a fellowship in pediatric gastroenterology/hepatology at Children’s Hospital of Pittsburgh/University of Pittsburgh Medical Center, while concurrently attending the Katz School of Business at the University of Pittsburgh, receiving an MBA in 2001. He completed his residency in pediatrics at the University of Medicine and Dentistry New Jersey (UMDNJ), Robert Wood Johnson University Hospital in New Brunswick, NJ.
After his residency, he earned additional certification and training for the management of gastrointestinal motility disorders at the University of Pittsburgh. He has also completed an introductory course on hypnosis training for functional gastrointestinal applications at the University of North Carolina, Chapel Hill.
Dr. Youssef completed his undergraduate studies at New York University’s Stern School of Business, graduating with a Bachelor’s degree in finance. He then attended the School of Medicine at Ross University on the island of Dominica in the West Indies.
Dr. Youssef has written for numerous publications, including the Journal of Pediatric Gastroenterology and Nutrition (March 2011), Seminars in Pediatric Surgery (April 2010) and the Journal of Economic Entomology (November 2009). In addition, as a clinical development leader at pharmaceutical companies, he has won international research awards and helped develop agents with unique mechanisms of action focused on motility to treat gastroesophageal reflux disease (GERD), opioid-induced constipation, and intestinal failure related to short bowel syndrome.
